Free shipping on all orders over $ 500

SR-4835

Cat. No. M10258

All AbMole products are for research use only, cannot be used for human consumption.

SR-4835 Structure
Synonym:

SR4835

Size Price Availability Quantity
10mM*1mL in DMSO USD 134  USD134 In stock
1mg USD 50  USD50 In stock
5mg USD 110  USD110 In stock
10mg USD 189  USD189 In stock
25mg USD 390  USD390 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

SR-4835 is a highly selective, dual inhibitor of CDK12 and CDK13 with IC50 values of 99 nM, Kd of 98 nM and Kd of 4.9 nM, respectively. SR-4835 has potent in vivo anti-TNBC activity and augments the anti-cancer activity of cisplatin, irinotecan, and olaparib, which are standard-of-care therapeutics for TNBC.

Protocol (for reference only)
Cell Experiment
Cell lines MDA-MB-231, MDA-MB-436, HS578T, MDA-MB-468, FHC
Preparation method Clonogenic Assays. 500 cells per well are plated in six-well dishes in triplicate. After overnight incubation, SR-4835 is added to the medium for 72 hr, and cells are allowed to grow for 7 to 10 days, during which medium is changed every 2 to 3 days.
Concentrations 10-90 nM, 0.4-10 μM
Incubation time 4 h, 6 h, 72 h
Animal Experiment
Animal models Female SCID Beige mice bearing xenograft models BCM-4013 and BCM-3887
Formulation prepared in 10/90 DMSO/30% Hydroxypropyl-β-Cyclodextrin (hp-BCD) in water
Dosages 20 mg/kg
Administration PO 5 days per week
Chemical Information
Molecular Weight 499.36
Formula C21H20Cl2N10O
CAS Number 2387704-62-1
Solubility (25°C) DMSO ≥ 6 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Jessica L Hopkins, et al. Cancer Cell. Induction of BRCAness in Triple-Negative Breast Cancer by a CDK12/13 Inhibitor Improves Chemotherapy

[2] Victor Quereda, et al. Cancer Cell. Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer

Related CDK Products
(E/Z)-Zotiraciclib citrate

(E/Z)-Zotiraciclib citrate is a potent CDK2, JAK2, and FLT3 inhibitor.

Abemaciclib metabolites M2

Abemaciclib metabolite M2 (LSN2839567) is a metabolite of Abemaciclib, acts as a potent CDK4 and CDK6 inhibitor, with IC50 values of 1.2 and 1.3 nM, respectively.

CDK9-IN-1

CDK9-IN-1 is a novel, selective CDK9 inhibitor, with an IC50 of 39 nM for CDK9/CycT1, it can be used for the research of HIV infection.

XO44

XO44 (PF-6808472) is a broad-spectrum covalent kinase probe.

ML 315 

ML 315 is a selective dual inhibitor of CDK and DYRK with IC50s of 68 nM and 282 nM, respectively.

  Catalog
Abmole Inhibitor Catalog




Keywords: SR-4835, SR4835 supplier, CDK, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.